Literature DB >> 35210319

The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study.

Kevin Mortimer1,2, Maia Lesosky3,4, Luis García-Marcos5,6, M Innes Asher7, Neil Pearce8, Eamon Ellwood7, Karen Bissell9, Asma El Sony10, Philippa Ellwood7, Guy B Marks11, Antonela Martínez-Torres12,13, Eva Morales14, Virginia Perez-Fernandez15, Steven Robertson8, Charlotte E Rutter8, Richard J Silverwood8,16, David P Strachan17, Chen-Yuan Chiang18,19,20.   

Abstract

AIMS: Asthma, hay fever and eczema are three common chronic conditions. There have been no recent multi-country data on the burden of these three conditions in adults; the aims of this study are to fill this evidence gap.
METHODS: The Global Asthma Network Phase I is a multi-country cross-sectional population-based study using the same core methodology as the International Study of Asthma and Allergies in Childhood Phase III. It provides data on the burden of asthma, hay fever and eczema in children and adolescents, and, for the first time, in their parents/guardians.
RESULTS: Data were available from 193 912 adults (104 061 female; mean±sd age 38±7.5 years) in 43 centres in 17 countries. The overall prevalence (range) of symptoms was 6.6% (0.9-32.7%) for current wheeze, 4.4% (0.9-29.0%) for asthma ever, 14.4% (2.8-45.7%) for hay fever ever and 9.9% (1.6-29.5%) for eczema ever. Centre prevalence varied considerably both between countries and within countries. There was a moderate correlation between hay fever ever and asthma ever, and between eczema ever and hay fever ever at the centre level. There were moderate to strong correlations between indicators of the burden of disease reported in adults and the two younger age groups.
CONCLUSION: We found evidence for a substantial burden of asthma, hay fever ever and eczema ever in the countries examined, highlighting the major public health importance of these diseases. Prevention strategies and equitable access to effective and affordable treatments for these three conditions would help mitigate the avoidable morbidity they cause.
Copyright ©The authors 2022.

Entities:  

Mesh:

Year:  2022        PMID: 35210319      PMCID: PMC9474894          DOI: 10.1183/13993003.02865-2021

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   33.795


  30 in total

1.  The European Community Respiratory Health Survey II.

Authors: 
Journal:  Eur Respir J       Date:  2002-11       Impact factor: 16.671

2.  Translation of questions: the International Study of Asthma and Allergies in Childhood (ISAAC) experience.

Authors:  P Ellwood; H Williams; N Aït-Khaled; B Björkstén; C Robertson
Journal:  Int J Tuberc Lung Dis       Date:  2009-09       Impact factor: 2.373

3.  Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood.

Authors:  H Williams; C Robertson; A Stewart; N Aït-Khaled; G Anabwani; R Anderson; I Asher; R Beasley; B Björkstén; M Burr; T Clayton; J Crane; P Ellwood; U Keil; C Lai; J Mallol; F Martinez; E Mitchell; S Montefort; N Pearce; J Shah; B Sibbald; D Strachan; E von Mutius; S K Weiland
Journal:  J Allergy Clin Immunol       Date:  1999-01       Impact factor: 10.793

4.  Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS).

Authors: 
Journal:  Eur Respir J       Date:  1996-04       Impact factor: 16.671

5.  Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three.

Authors:  Joseph A Odhiambo; Hywel C Williams; Tadd O Clayton; Colin F Robertson; M Innes Asher
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

6.  Pollen counts in relation to the prevalence of allergic rhinoconjunctivitis, asthma and atopic eczema in the International Study of Asthma and Allergies in Childhood (ISAAC).

Authors:  M L Burr; J C Emberlin; R Treu; S Cheng; N E Pearce
Journal:  Clin Exp Allergy       Date:  2003-12       Impact factor: 5.018

7.  Climate and the prevalence of symptoms of asthma, allergic rhinitis, and atopic eczema in children.

Authors:  S K Weiland; A Hüsing; D P Strachan; P Rzehak; N Pearce
Journal:  Occup Environ Med       Date:  2004-07       Impact factor: 4.402

8.  Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee.

Authors: 
Journal:  Lancet       Date:  1998-04-25       Impact factor: 79.321

Review 9.  The atopic march: Critical evidence and clinical relevance.

Authors:  David A Hill; Jonathan M Spergel
Journal:  Ann Allergy Asthma Immunol       Date:  2018-02       Impact factor: 6.347

10.  Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study.

Authors:  M Innes Asher; Charlotte E Rutter; Karen Bissell; Chen-Yuan Chiang; Asma El Sony; Eamon Ellwood; Philippa Ellwood; Luis García-Marcos; Guy B Marks; Eva Morales; Kevin Mortimer; Virginia Pérez-Fernández; Steven Robertson; Richard J Silverwood; David P Strachan; Neil Pearce
Journal:  Lancet       Date:  2021-10-28       Impact factor: 202.731

View more
  1 in total

Review 1.  Asthma management in low and middle income countries: case for change.

Authors:  Kevin Mortimer; Helen K Reddel; Paulo M Pitrez; Eric D Bateman
Journal:  Eur Respir J       Date:  2022-09-15       Impact factor: 33.795

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.